MDAT
Chemical compound
- none
- In general: uncontrolled
- 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine
- 101625-35-8 Y
- hydrochloride: 3446-21-8 Y
- 36483
- 33531
- 28IR5LC41Q
- hydrochloride: BOX4U52EET Y
- DTXSID501017047
- Interactive image
- C3Cc1cc2OCOc2cc1CC3N
6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.
See also
References
- ^ a b Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651.
- v
- t
- e
amines
(other than
cathinones)
- Unfused benzene ring: 3-CMA
- 4-CAB
- 4-FA
- 4-MA
- 4-MMA
- 4-FMA
- 4-MTA
- 4,4'-DMAR
- Ariadne
- Metaescaline
- MMA
- PMA
- PMEA
- PMMA
- mMMA
Benzodioxine: EDMA
Benzodioxoles: Phenethylamine: { Lophophine } - Amphetamines: { 2-Methyl-MDA
- 2,3-MDA
- 3,4-MDA (tenamfetamine)
- 5-Methyl-MDA
- 6-Methyl-MDA
- DFMDA
- DMMDA
- DMMDA-2
- EIDA
- Lys-MDA
- MDEA
- MDMA (midomafetamine)
- MDMOH
- MDOH
- MMDA
- MMDA-2
- MMDMA
- N-t-BOC-MDMA }
- 1-Phenylbutan-2-amines: { BDB
- EBDB
- MBDB }
- Phentermines: { MDMP
- MDPH }
Benzofurans, dihydrobenzofurans and benzothiophenes: 2-MAPB - 5-APB
- 5-APDB
- 5-EAPB
- 5-MAPB
- 5-MAPDB
- 5-MAPBT
- 5-MBPB
- 6-APB
- 6-APDB
- 6-EAPB
- 6-MAPB
- 6-MAPDB
- IBF5MAP
Indanes: 5-APDI - 5-MAPDI
Indoles: 5-IT - 6-API
Naphthalenes: Methamnetamine - Naphthylaminopropane
Tetralin: 6-APT
alkylamines